Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and Mounjaro.

We recently published a list of Jim Cramer Was Talking About These 10 Stocks Amid Trump’s Trade Wars. In this article, we are going to take a look at where Eli Lilly (NYSE:LLY) stands against other stocks that Jim Cramer was talking about amid Trump’s trade wars.

Eli Lilly sues two compounders over tirzepatide after FDA lifts Zepbound, Mounjaro shortage status in key GLP-1 legal test.

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain for investors.

Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 agonists could be evolving, and Eli Lilly has a high-stakes opportunity to dominate it over the coming year.

With two new lawsuits, Eli Lilly (NYSE: LLY) has escalated its legal campaign against the makers of unauthorized versions of its diabetes and weight-loss drugs, Mounjaro (tirzepatide) and Zepbound (tirzepatide),

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges. Find out who is the winner.

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings to offset any impact from impending restrictions on se